- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- LPCN 1144 Formulation A, LPCN 1144 Formulation B, Placebo
- Drug
- Lead sponsor
- Lipocine Inc.
- Industry
- Eligibility
- 18 Years to 80 Years · Male only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 19
- States / cities
- El Cajon, California • Murrieta, California • Rialto, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 50,407
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Depression, Major Depressive Disorder
- Interventions
- Buprenorphine, Placebo
- Drug
- Lead sponsor
- Jordan F. Karp
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Fresolimumab
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Houston, Texas
- Conditions
- Exercise-induced Bronchospasm
- Interventions
- albuterol aerosol by HFA MDI, albuterol aerosol by HFA BOI, placebo aerosol by HFA
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Englewood, Colorado • Lakewood, Colorado
- Conditions
- Leukemia
- Interventions
- fludarabine phosphate, thalidomide
- Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Sleep, Pediatrics, Adenotonsillectomy
- Interventions
- Not listed
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Renal Impairment
- Interventions
- 50 mg Proellex
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 48 Years · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
- Conditions
- Healthy Adult Participants, Synaptic Plasticity
- Interventions
- PET Imaging Scan using [11C]UCB-J
- Radiation
- Lead sponsor
- Beatriz Luna
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Solid Tumors, Lymphoma, Multiple Myeloma
- Interventions
- CS-7017 and Bexarotene
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Asthma
- Interventions
- Reslizumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arkansas + 62 more
- Conditions
- Asthma
- Interventions
- Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg, Albuterol sulfate metered-dose inhaler 180 μg
- Combination Product · Drug
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 3,132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 170
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 139 more
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
- Interventions
- PF-07820435, Sasanlimab
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Sarasota, Florida • Grand Rapids, Michigan • Nashville, Tennessee
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Macitentan, Standard-of-care
- Drug · Other
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
- Conditions
- Down Syndrome, Cognitive Dysfunction
- Interventions
- Aricept (Donepezil hydrochloride), Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 6 Years to 10 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 2
- States / cities
- San Antonio, Texas • Herndon, Virginia
- Conditions
- Asthma
- Interventions
- tiotropium-bromide, placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 1 Year to 5 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Columbia, Missouri • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more
- Conditions
- Dengue
- Interventions
- Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
- Biological
- Lead sponsor
- State University of New York - Upstate Medical University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Atopic Dermatitis
- Interventions
- LEO 152020 tablet, LEO 152020 placebo tablet
- Drug
- Lead sponsor
- JW Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Los Angeles, California • San Diego, California + 3 more
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Bortezomib, CHOP, Rituximab
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Omaha, Nebraska • New York, New York
- Conditions
- Influenza Infection
- Interventions
- VRC-FLUNPF099-00-VP (H1ssF_3928)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Inhaled PT001, Inhaled Placebo, Tiotropium Handihaler
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 6
- States / cities
- Peoria, Arizona • Denver, Colorado • Miami, Florida + 3 more
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
- Interventions
- PLX3397, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more
- Conditions
- Hepatitis B
- Interventions
- GSK3228836, PegIFN, NA therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Sacramento, California • Iowa City, Iowa • Detroit, Michigan + 1 more
- Conditions
- Age Related Macular Degeneration
- Interventions
- Fluocinolone Acetonide/Medidur
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Venous Thrombosis
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Active comparator, Rivaroxaban (BAY59-7939) suspension
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Orange, California + 10 more